期刊文献+

88例原发性醛固酮增多症临床回顾分析 被引量:4

Primary aldosteronism :a retrospective analysis of 88 cases
原文传递
导出
摘要 目的提高对原发性醛固酮增多症(简称原醛)的诊治水平。方法回顾性分析88例原醛患者的临床资料。结果血压水平、血浆醛固酮浓度(PAC)升高,血浆肾素活性(PRA)、血清钾离子浓度下降。醛固酮瘤占84.09%,特发性醛固酮增多症(简称特醛症)占15.91%。95.45%患者的血浆醛固酮/血浆肾素活性比值(ARR)〉20。醛固酮瘤患者具有更高的血浆醛固酮水平及更低的血浆肾素活性和血清钾离子浓度。结论ARR是原醛的重要筛查方法;卧立位试验及CT有助于肾上腺皮质腺瘤和增生的鉴别。 Objective To elevate the diagnosis and treatment of primary aldosteronism. Methods 88 cases of primary aldosteronism were reviewed. Result To all the patients, the average levels of SBP- max and DBPmax were( 187.66 ± 3.03 ) mm Hg and( 113.14 ± 1.78 ) mm Hg respectively. The mean value of plasma renin activity(PRA) and Plasma aldosterone concentration(PAC) were( 123.42 ± 20.17 )pmol · L^-1 · h^-1 and(690.03 ± 39.10)pmol · L^-1 severally. Of the 88 patients,95.45% had PAC/PRA (ARR) above 20.84.09% of the patients were caused by aldosterone producing adenoma(APA) and 15.91% were caused by idiopathic hypersteronism (IHA). Serum potassium was lower in APA as compared to IHA 3.22 mmol· L ^- 1 vs 3.74 mmol· L ^- 1 ( p 〈 0. 05 ). The PRA of the APA was lower than the IHA as well,37.20 pmol · L ^- 1· h^ -1 vs 96.51 pmol · L^- 1 · h ^- 1 ( p 〈 0.05 ). The PAC of APA was higher than the IHA 679.70 pmol · L ^- 1 vs 477.49 pmol · L ^- 1 ( p 〈 0.05 ) correspondingly. Spironolactone test was positive in all patients. Conclusions ARR plays the important role in screening of PA. Postural stimulation test and CT were helpful to differentiate aldosterone producing adenoma and idiopathic aldosteronism.
出处 《临床内科杂志》 CAS 2010年第1期40-42,共3页 Journal of Clinical Internal Medicine
关键词 原发性醛固酮增多症 醛固酮 肾素活性 醛固酮/肾素活性比值 Primary aldosteronism Aldosterone Renin activity Aldosterone/renin aetivity ratio
  • 相关文献

参考文献11

  • 1William F,Young Jr. Primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology,2003,144 : 2208 -2213.
  • 2Cecilia M, William F, Young Jr. Primary aldosteronsim : diagnostic and treatment strategies. Nephrology ,2006,4 : 198-208.
  • 3杨建梅,郭晓蕙,董爱梅,田曙光.原发性醛固酮增多症的临床特点[J].临床荟萃,2005,20(24):1381-1384. 被引量:21
  • 4Gian PR, Giampaolo B, Chiara C, et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1125 Hypertensive Patierlts. J Am Coll Cardiol,2006 ,48 :2293-2300.
  • 5Kaplan NM. The current epidemic of primary aldosteronism : causes and consequences. Hypertension,2004,22 : 863-869.
  • 6Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension ,2002,40:892-896.
  • 7Gordon RD, Stowasser M, Klemm SA, et al. Primary aldosteronism some genetic, morphological, and biochemical aspects of subtypes. Steroids, 1995.60:35-41.
  • 8Gordon RD, Laragh JH, Funder JW, et al. Low reniu hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab,2005,16 : 108-113.
  • 9Sau-Cheung Tiu, Cheung-Hei Choi, Chi-Chung Shek, et al. The Use of Aldosterone-Renin Ratio as a Diagnostic Test for Primary Hyperaldosteronism and Its Test Charaeteristics under Different Conditions of Blood Sampling. Clin Endoerinol Metab,2005,90:72-78.
  • 10Gary L, Schwartz Stephen T. Turner. Screening for Primary Aldosteronism in Essential Hypertension : Diagnostic Accuracy of the Ratio of Plasma Aldostel, one Concentration to Plasma Renin Activity. Clinical Chemistry ,2005,51:386-394.

二级参考文献11

  • 1刘雪娜,周宪梁,刘亚欣,顾晴,陈改玲,孙晓昕,丰雷,惠汝太.原发性醛固酮增多症合并高血浆肾素活性的临床病例分析[J].中国分子心脏病学杂志,2004,4(4):233-234. 被引量:1
  • 2MULATERO P,STOWASSER M, LOH K C.Increased diagnosis of primary aldosteronism,including surgically correctable forms,in centers from five continents[J]. J Clin Endocrinol Metab,2004,89(3):1045-1050.
  • 3YOUNG W F Jr.Minireview:primary aldosteronism-changing concepts in diagnosis and treatment[J]. Endocrinology,2003,144(6):2208-2213.
  • 4STRUTHERS A D. Aldosterone-induced vasculopathy[J]. Molecular and Cellular Endocrinology,2004,217(1-2):239-241.
  • 5ROSSI G P, DI B V, GANZAROLI C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism[J]. Hypertension,2002,40(1):23-27.
  • 6MILLIEZ P,GIRERD X,PLOUIN P F.Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol,2005,45(8):1243-1248.
  • 7STOWASSER M, GORDON R D. Primary aldosteronism-careful investigation is essential and rewarding[J]. Molecular and Cellular Endocrinology,2004,217(1-2):33-39.
  • 8STOWASSER M,GORDON R D,GUNASEKERA T G,et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective' screening of hypertensive patients[J]. J Hypertens,2003,21(11):2149-2157.
  • 9CONN J W, COHEN E L,ROVNER D R,et al. Normokalemic primary aldosteronism. A detectable cause of curable “essential” hypertension[J]. JAMA,1965,19(193):200-206.
  • 10ROSSI E, REGOLISTI G, NEGRO A, et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives[J]. Am J Hypertens,2002,15(10 Pt 1):896-902.

共引文献20

同被引文献33

  • 1张惠兰,刘振江,邵娇梅,严江涛,汪道文.血浆醛固酮/肾素活性比值在诊断原发性醛固酮增多症患者的价值[J].中华心血管病杂志,2006,34(10):873-876. 被引量:17
  • 2Wilson JD.Williams Texbook of Endocrinology.(9th Edition)Philadelphia:W B Saunder Company,1998.595-598.
  • 3Young W F Jr.Minireviewprimary aldosteronism-changing concepts in diagnosis and treatment.Endocrinology,2003,144:2208-2213.
  • 4Sywak M,Pasieka JL.Long-tern follow-up and cost benefit of adrenaletomy in patients in prients with primary hyperaldosterunism.Br J Surg,2002,89:1587-1589.
  • 5Calhoun DA.Aldosteronism and hypertension.Clin J Am Soc Nephrol,2006,1:1039-1045.
  • 6Catena C,Colussi G,Nadalini E,et al.Cardiovascular outcomes in patients with primary aldosteronism after treatment.Arch Intern Med,2008,168:80-85.
  • 7Sechi LA,Novello M,Lapenna R,et al.Long-term renal outcomes in patients with primary aldosteronism.JAMA,2006,295:2638-2645.
  • 8Funder JW,Carey RM,Fardella C,et al.Case detection,diagnosis,and treatment of patients with primary aldosteronism:an endocrine society clinical practice guideline.J Clin Endocrinol Metab,2008,93:3266-3281.
  • 9Bauersachs J,Heck M,Fraccarollo D,et al.Addition of spironolactone to angiotensin——converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction:role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.J Am Coll Cardiol,2002,39:351-358.
  • 10Duprez DA.Aldosterone and the vasculature:mechanisms mediating resistant hypertension.J Clin Hypertens (Greenwich),2007,9 (suppl 1):13-18.

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部